Ashok B Jain
Affiliation: University of Pittsburgh
- Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 yearsA Jain
Departments of Surgery, Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
Liver Transpl 7:623-30. 2001..05) was the only factor found to be significant between patients who had graft loss versus those who recovered...
- Hepatitis C virus and renal failureA K B Jain
Thomas E Starzl Transplantation Institute, Pittsburgh, Pennsylvania 15213, USA
Transplant Proc 35:416-8. 2003
- Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infectionAshok B Jain
Transplantation Institute, The Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA
Liver Transpl 8:1007-13. 2002..Further pharmacokinetic studies of ribavirin in LTx patients with varying degrees of renal function may allow the development of an algorithm for the safer use of ribavirin in HCV-positive LTx patients...
- The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patientsAshok Kumar B Jain
Department of Surgery, Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
Liver Transpl 8:841-5. 2002..Great caution and frequent drug level monitoring are necessary when HAART is introduced or withdrawn in HIV-positive recipients of organ transplants...
- Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case reportAshok Kumar B Jain
Department of Surgery, University of Pennsylvania, Philadelphia, PA, USA
Liver Transpl 8:838-40. 2002..Increase in trough concentration, peak concentration area under the curve concentration, and prolongation of half-life of sirolimus has been shown in a patient who was on a low dose (one fifth the recommended dose) of nelfinavir...
- Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus-positive liver and kidney transplantation patientsA K B Jain
Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, 3601 Fifth Avenue, Falk Medical Building 4th Floor, Pittsburgh, PA 15213, USA
Transplant Proc 34:1540-1. 2002
- Steroid withdrawal under tacrolimus for primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis after liver transplantation and long-term survivalAshok Jain
Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
Transplant Proc 34:1524-5. 2002
- A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis CAshok Jain
Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Liver Transpl 8:40-6. 2002..In addition, there was no difference in HAI or fibrosis score between the two groups. Either MMF has no anti-HCV effect or its immunosuppressive properties overwhelm its antiviral effect in the clinical setting...
- Phenytoin decreases the blood concentrations of sirolimus in a liver transplant recipient: a case reportJonathan A Fridell
Department of Surgery, Indiana University School of Medicine, Indianapolis, USA
Ther Drug Monit 25:117-9. 2003..It is essential to monitor the blood concentrations of sirolimus and adjust the sirolimus dosage when phenytoin administration begins or ends...
- Conversion from tacrolimus to cyclosporine--a based immunosuppression following liver transplantationCataldo Doria
Department of Surgery, Division of Transplantation, Thomas Jefferson University, Philadelphia, PA 19107, USA
Exp Clin Transplant 1:48-55. 2003..Additionally, re-conversion to Tacrolimus for lack of efficacy of Cyclosporine A did not appear to be associated with a recurrence of the condition that caused the initial switch...